{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:21:09Z","timestamp":1792678869137,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.breast.2026.104739","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:27:51Z","timestamp":1771288071000},"page":"104739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["BRCA1\/2, PALB2 mutations and first-line CDK4\/6 inhibitor efficacy in HR+ metastatic breast cancer"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3321-5024","authenticated-orcid":false,"given":"Timoth\u00e9","family":"Guinel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Lusque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mailliez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"de la Motte Rouge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desmoulins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Arnedos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bailleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Delaloge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-0561","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Fr\u00e9nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.breast.2026.104739_bib1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41416-024-02827-z","article-title":"BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing","volume":"131","author":"Arun","year":"2024","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2026.104739_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, Version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"12","key":"10.1016\/j.breast.2026.104739_bib3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.breast.2026.104739_bib4","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40487-021-00162-4","article-title":"A real-world evidence study of CDK4\/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by germline BRCA mutation status","volume":"9","author":"Collins","year":"2021","journal-title":"Oncol Ther"},{"issue":"1","key":"10.1016\/j.breast.2026.104739_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101399","article-title":"210P real-world outcomes in patients (pts) with HR+\/HER2\u2013 metastatic breast cancer (mBC) and germline\/tumour BRCA mutations (g\/tBRCA1\/2m) receiving 1st-line (1L) CDK4\/6i plus endocrine therapy (ET)","volume":"8","author":"Safonov","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104739_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104825","article-title":"270P first-line cyclindependent kinase 4\/6 inhibitors (CDK4\/6i) in patients with a homologous recombination repair (HRR) germline pathogenic variant (PV) and breast cancer (BC): clinical outcomes and mechanisms of resistance","volume":"10","author":"Lapena","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104739_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.654","volume":"34","author":"Palazzo","year":"2023","journal-title":"Ann Oncol"},{"issue":"4_Supplement","key":"10.1016\/j.breast.2026.104739_bib8","doi-asserted-by":"crossref","first-page":"GS4","DOI":"10.1158\/1538-7445.SABCS21-GS4-08","article-title":"Abstract GS4-08: comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating . therapy resistance","volume":"82","author":"Safonov","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104739_bib9","series-title":"Recommandation en sant\u00e9 publique","article-title":"D\u00e9pistage du cancer du sein en France : identification des femmes \u00e0 haut risque et modalit\u00e9s de d\u00e9pistage","year":"2014"},{"issue":"11","key":"10.1016\/j.breast.2026.104739_bib10","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/ejhg.2014.16","article-title":"Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes","volume":"22","author":"Castera","year":"2014","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.breast.2026.104739_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.759150","article-title":"Which clinicopathologic parameters suggest primary resistance to palbociclib in combination with letrozole as the first-line treatment for hormone receptor-positive, HER2-negative advanced breast cancer?","volume":"11","author":"Kim","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104739_bib12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-022-06566-8","article-title":"Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy","volume":"196","author":"Park","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.breast.2026.104739_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00140","article-title":"Cyclin-dependent kinase 4\/6 inhibitor outcomes in patients with advanced breast cancer carrying germline pathogenic variants in DNA repair\u2013related genes","volume":"6","author":"Bruno","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.breast.2026.104739_bib14","volume":"vol. 33","author":"Rodriguez Hernandez","year":"2022"},{"key":"10.1016\/j.breast.2026.104739_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.301","article-title":"353P clinical outcomes of treatment with CDK4\/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2","volume":"35","author":"Scheel","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104739_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.breast.2022.01.014","article-title":"Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"62","author":"Lee","year":"2022","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.breast.2026.104739_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13073-023-01201-7","article-title":"Longitudinal multi-omics study of palbociclib resistance in HR-positive\/HER2-negative metastatic breast cancer","volume":"15","author":"Park","year":"2023","journal-title":"Genome Med"},{"key":"10.1016\/j.breast.2026.104739_bib18","first-page":"83","article-title":"Impact of germline BRCA1\/2 status on outcomes for patients with HR+\/HER2- metastatic breast cancer treated with CDK4\/6 inhibitors: a systematic review and meta-analysis","volume":"22","author":"Bottosso","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104739_bib19","series-title":"Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer","author":"Safonov","year":"2024"},{"issue":"3","key":"10.1016\/j.breast.2026.104739_bib20","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s11030-024-10964-z","article-title":"Advancements in targeting tumor suppressor genes (p53 and BRCA 1\/2) in breast cancer therapy","volume":"29","author":"Chahat","year":"2025","journal-title":"Mol Divers"},{"issue":"5","key":"10.1016\/j.breast.2026.104739_bib21","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/1078-0432.CCR-08-0640","article-title":"The complex relationship between BRCA1 and ER\u03b1 in hereditary breast cancer Julia J","volume":"15","author":"Gorski","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2026.104739_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41523-025-00859-z","article-title":"Real-world effectiveness of PARP inhibitors after CDK4\/6 inhibitor therapy in BRCA-mutated HR-positive\/HER2-negative advanced breast cancer","volume":"11","author":"Zattarin","year":"2025","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.breast.2026.104739_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103201","volume":"9","author":"Guiu","year":"2024","journal-title":"ESMO Open"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:32:08Z","timestamp":1775683928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":23,"alternative-id":["S0960977626000494"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104739","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRCA1\/2, PALB2 mutations and first-line CDK4\/6 inhibitor efficacy in HR+ metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104739","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104739"}}